Johnson & Johnson’s closely watched patent infringement lawsuit against rival Boston Scientific Corp. over drug-coated stents has gone to the jury following closing arguments on Monday.
In a case with broad implications for antitrust suits against patent holders, the U.S. Supreme Court said Monday it would hear an appeal by Illinois Tool Works Inc. over business contracts in a market where a company enjoys presumed monopoly powers arising from patents.
A U.S. district court judge has ruled in favor of U.K. diagnostics and medical products group Medisys in a patent dispute with Swiss rival Roche Diagnostics Corp. over blood glucose monitors used by diabetics.
McDermott, Will & Emery has grown its intellectual property group just the way it has grown the firm: through an aggressive series of acquisitions and bulk lateral hires.
In a setback for French drug maker Sanofi-Aventis SA, a California federal court has granted a motion for summary judgment for inequitable conduct in a patent dispute with generics makers Amphastar and Teva Pharmaceuticals USA over the anti-thrombotic medication Lovenox.
Johnson & Johnson has rebuffed an offer to begin settlement talks by rival Boston Scientific in their patent dispute over drug-coated stents, Boston Scientific told the Boston Globe.
European antitrust authorities have fined Anglo-Swedish drug maker AstraZeneca PLC €60 million for abusing patent systems to thwart generic competition for the blockbuster ulcer drug Losec.
With a decision looming in the Supreme Court’s review of the music industry’s lawsuit against online file sharing network Grokster, the spotlight is once again back on the small but influential litigation outfit Keker & Van Nest LLP.
In the first European antitrust crackdown on patent abuse, the European Commission is expected to fine AstraZeneca on Wednesday for systematically exploiting patent regulations to thwart generic competition.
Johnson & Johnson Inc. sued Boston Scientific Corp. for patent infringement lawsuit because the company is being beaten in the market for cardiovascular stents, a lawyer for Boston Scientific told the jury at the opening of a closely watched trial Monday.
Jury selection begins Monday in the closely watched patent dispute between Johnson & Johnson and Boston Scientific Corp. over the lucrative $5 billion market for drug-coated heart stents.
In a landmark decision with broad implications for the pharmaceutical industry, the U.S. Supreme Court has ruled that drug makers can ignore their competitors' patents during research on rival treatments.
A Dutch court has ruled that a Johnson & Johnson subsidiary, Cordis Europa, infringed a patent for medical device maker Boston Scientific's balloon catheter.
King Pharmaceuticals and Astellas Pharmaceuticals have filed a lawsuit against Israeli generics maker Teva Pharmaceutical for infringing violating King's patent on pharmacologic stress agent Adenoscan.
Abbott Laboratories has settled a patent dispute with Israeli drug maker Teva Pharmaceutical Industries Ltd. over a generic version of Abbott's best-selling cholesterol treatment TriCor.
In a major setback for Purdue Pharma, Endo Pharmaceutical Holdings Inc. has won an appeals court ruling allowing it to sell a generic version of the painkiller OxyContin.
In a decision with broad implications for the pharmaceutical industry, a U.S. appeals court has ruled that brand-name drug companies have the right to sell unbranded versions of their own drugs even if they undercut sales of generic competitors.
Medical device makers Thermage and Syneron have settled their patent battle over ways of tightening and treating skin using light and radio waves.
Swiss drug maker Roche and licensee Allergan Inc. have sued Canadian generics maker Apotex in a California federal court over its plans to make a generic version of the eye-inflammation treatment Acular.
A judge with a federal district court in Illinois has granted Abbott Laboratories a preliminary injunction against Teva Pharmaceutical Industries Ltd. to keep the Israeli drug maker from launching a generic extended-release version of the antibiotic Biaxin.